Dr. Chan Discusses Cabozantinib for the Treatment of NETs

November 1, 2017
Jennifer Chan MD, MPH

Jennifer Chan, MD, MPH, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, discusses a study exploring cabozantinib (Cabometyx) for the treatment of patients with advanced carcinoid and pancreatic neuroendocrine tumors.